C-BI27Puretech
validated efficacy, oral administration, tolerability
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-BI27
C-BI27C-BI27validated efficacy, oral administration, tolerability
0-100 chain-logic scale · 15 dimensions · scored on public evidence
This week, we speak with John Friend, CEO of Kazia Therapeutics; and have a conversation with PureTech Health CEO Robert Lyne and Eric Elenko, president and co-founder of PureTech and acting CEO of Gallop Oncology. Times: 03:23 Kazia Therapeutics 31:56 PureTech Health PureTech Health PureTech Health plc is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. The company recently announced positive topline data from its phase 1b clinical trial of LYT-200, a first-in-class, fully human anti-galectin-9 monoclonal antibody, in heavily pretreated patients with relapsed/refractory (R/R) high-risk (HR) myelodysplastic syndrome (MDS) and R/R acute myeloid leukaemia (AML). Based on the results, PureTech's founded entity, Gallop Oncology, has selected a recommended phase 2 dose (RP2D) and intends to engage with the U.S. Food and Drug Administration (FDA) to discuss the design of a subsequent trial that could potentially support regis
Promising drugs can become abandoned or underused because of tolerability issues, poor drug‑like properties, or other fixable limitations, even when there is already compelling human evidence that they work. PureTech Health starts with an unmet need and human pharmacology, then systematically dissects and solves the specific liabilities of discontinued drugs to unlock breakthroughs in an approach that has proved to be a highly efficient means of value creation. Eric Elenko, president and co‑founder of PureTech, discusses the company’s disciplined approach to drug innovation around rescuing promising but discontinued therapeutics, its hub‑and‑spoke structure, and how this model can neutralize emotional bias, enforce clear success criteria, and turn partially derisked assets into commercial successes.
This is a study for adults with a lung disease called idiopathic pulmonary fibrosis. The main purpose of this study is to look at how well deupirfenidone improves lung function and how safe it is for people with idiopathic pulmonary fibrosis (IPF) when compared with pirfenidone. Participants may have been treated with an approved antifibrotic drug for up to a year in the past, but they cannot be on background antifibrotic treatment during this study. Participants will be randomly assigned (meaning by chance) to take either deupirfenidone or pirfenidone 3 times a day, and neither a participant nor their study team will know which study drug participants are on. Participants will be in the study for up to approximately 3 years. During the first year, participants visit the study site up to ten times and afterwards they visit the site every three months. All participants will remain on blinded study drug until the last participant has completed Week 52 Visit. They will have lung function tests, a check of their health, and will tell the study team about any unfavorable effects.
This is a trial of up to 60-day duration for safety, tolerability, and pharmacokinetics in healthy volunteers administered deupirfenidone (LYT-100) alone or in combination with nintedanib .
A Phase 1 Open-label, Multi-center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT- 200 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), or with Relapsed/refractory, High-risk Myelodysplastic Syndrome (MDS)
This study a randomized, double-blind, four arm study to evaluate the safety and efficacy of LYT-100 compared to pirfenidone or placebo in adults with Idiopathic Pulmonary Fibrosis.
Part 1 is a single ascending dose (SAD) trial in healthy volunteers (HV) to assess the safety, tolerability, and pharmacokinetic (PK) profile of orally administered LYT-300. Part 2 is a crossover assessment in HV of the effects of food on the safety, tolerability, and PK profile of orally administered LYT-300. Part 3 is a multiple ascending dose (MAD) trial in HV to assess the safety, tolerability, and PK profile of multiple doses (up to 7 days) of orally administered LYT-300. Part 4 is an assessment of the effects of LYT-300 vs. placebo on pharmacodynamic and patient reported outcome response to a validated clinical model of anxiety.
A three-part, randomized, double-blind study in healthy older adults to identify a dose of deupirfenidone for further clinical study.
A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab in Patients with Metastatic Solid Tumors
This study is being conducted in two parts, A and B. Part A is a randomized, double-blind, parallel arm study to evaluate the safety and efficacy of LYT-100 compared to placebo in adults with post-acute COVID-19 respiratory complications. Part B is an Open Label Extension (OLE) study for patients who complete Part A.
This is a trial of up to 6-months duration for safety, tolerability, clinical efficacy assessments, PK and biomarkers analysis in breast carcinoma patients with secondary lymphoedema
Supporting Rare Diseases Research on Rare Disease Day | PureTech Health posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agr
PureTech Health - Wikipedia Jump to content Main menu Main menu move to sidebar hide Navigation Main page Contents Current events Random article About Wikipedia Contact us Contribute Help Learn to edit Community portal Recent changes Upload file Special pages Search Search Appearance Donate Create account Log in Personal tools Donate Create account Log in Contents move to sidebar hide (Top) 1 History 2 Operations 3 References 4 External links Toggle the table of contents PureTech Health 2 languages فارسی Simple English Edit links Article Talk English Read Edit View history Tools Tools move to … st 2019 . Retrieved 16 August 2019 . ^ "PureTech banks $171M in a London IPO to fund its biotech bets" . Fierce Biotech. 19 June 2015. Archived from the original on 16 August 2019 . Retrieved 16 August 2019 . ^ "PureTech Health surges as Karuna investment rockets 442%" . Proactive Investors. 19 November 2019. Archived from the original on 14 December 2019 . Retrieved 14 December 2019 . ^ "Gelesis raises $12 million for pill that staves off hunger" . BetaBoston.com . May 16, 2 … December 2019 . ^ "PureTech Health affiliate Vedanta Biosciences awarded $5.8m grant" . Sharecast. 5 December 2019. Archived from the original on 14 December 2019 . Retrieved 14 December 2019 . ^ "Positive Results From PureTech Affiliate Male Pattern Hair Loss Study" . Morning Star. 13 June 2019. Archived from the original on 1 March 2020 . Retrieved 14 December 2019 . ^ "PureTech Licenses Glyph Lymphatic Technology" . FT. 29 August 2017. Archived from the original on 15 Jan … the Creative Commons Attribution-ShareAlike 4.0 License ; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy . Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc. , a non-profit organization. Privacy policy About Wikipedia Disclaimers Contact Wikipedia Legal & safety contacts Code of Conduct Developers Statistics Cookie statement Mobile view Search Search Toggle the table of contents PureTech Health 2 langu
Base to Base Biotech | iHeart Your Library Podcasts News Base to Base Biotech Play Newest Follow The Base to Base Biotech podcast is a weekly look at what's happening in the world of biotech, with interviews with biotech leaders around the world. Whether it's a new drug, cutting-edge technology, product launches, new technology, major finding announcement or clinical trial results, Base to Base Biotech keeps you informed. The podcast is hosted by former biotech editor and broadcaster, the award-winning media veteran Jim Cornall. Base to Base is an Ayr Coastal Media Ltd production. Ep … nnounced its official launch, having raised approximately £1.5m in non-dilutive grant funding and capital from an oversubscribed pre-seed round. The funding enables Houdini Bio to validate its technology and achieve projected technical milestones in a third of the predicted time. The platform- a machine learning-guided DNA sequ... Read more Listen Watch Share Mark as Played Base to Base biotech podcast 64: Solving logistics challenges June 19, 2026 • 23 mins This week on Base … ping a non-invasive diagnostic for endometriosis. The company’s aim is to apply precision medicine to female health. The company was formed in 2022 by M... Read more Listen Watch Share Mark as Played Popular Podcasts © 2026 iHeartMedia, Inc. Help Privacy Policy Your Privacy Choices Terms of Use
Bharatt Chowrira, CEO & Eric Elenko, CoFounder & President of PureTech on Biotech Growth - Biotech 2050 Podcast | Podcast on Spotify
PureTech's Undervalued Opportunities and Portfolio Progress | Robert Lyne posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, y … owers 3w PureTech has built a model designed to repeatedly create, advance, and fund innovative therapeutic programs - an approach that has contributed to three FDA approvals and the creation of multiple Founded Entities ( Seaport Therapeutics , Celea Therapeutics, Gallop Oncology, and more) Our CEO Robert Lyne and President & Co-Founder Eric Elenko recently joined Jim Cornall on the Base to Base Biotech podcast to discuss the evolution of that model, recent portfolio pro … his post PureTech has built a model designed to repeatedly create, advance, and fund innovative therapeutic programs - an approach that has contributed to three FDA approvals and the creation of multiple Founded Entities ( Seaport Therapeutics , Celea Therapeutics, Gallop Oncology, and more) Our CEO Robert Lyne and President & Co-Founder Eric Elenko recently joined Jim Cornall on the Base to Base Biotech podcast to discuss the evolution of that model, recent portfolio pro
Base to Base biotech podcast 6… ‑ Base to Base Biotech ‑ Apple Podcasts Rechercher Accueil Nouveautés Classements Rechercher 29 mai 1 h 1 min Base to Base biotech podcast 61: Making tumours visible, and taking on tough challenges Base to Base Biotech Lire This week, we speak with John Friend, CEO of Kazia Therapeutics; and have a conversation with PureTech Health CEO Robert Lyne and Eric Elenko, president and co-founder of PureTech and acting CEO of Gallop Oncology. Times: 03:23 Kazia Therapeutics 31:56 PureTech Health PureTech Health PureTech Health plc is a hub-and-spoke biotherapeutics comp
Base to Base biotech podcast 6… - Base to Base Biotech - Apple Podcasts Search Home New Top Charts Search May 29 1hr 1min Base to Base biotech podcast 61: Making tumours visible, and taking on tough challenges Base to Base Biotech Play This week, we speak with John Friend, CEO of Kazia Therapeutics; and have a conversation with PureTech Health CEO Robert Lyne and Eric Elenko, president and co-founder of PureTech and acting CEO of Gallop Oncology. Times: 03:23 Kazia Therapeutics 31:56 PureTech Health PureTech Health PureTech Health plc is a hub-and-spoke biotherapeutics company dedicated to giv
PureTech Announces Board Change - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases PureTech Announces Board Change July 9, 2025 | 4 min read Twitter LinkedIn Facebook Email Print BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastatin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
PureTech thinks the ‘hub-and-spoke’ startup model is still a good bet. If only investors agreed. | BioPharma Dive Skip to main content CONTINUE TO SITE ➞ Don't miss tomorrow's biopharma industry news Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy . You can unsubscribe at anytime. Informa TechTarget | Healthcare Dive MedTech Dive PharmaVoice Xte
Stream episode Bharatt Chowrira, CEO & Eric Elenko, CoFounder & President of PureTech on Biotech Growth by Biotech2050 Podcast podcast | Listen online for free on SoundCloud SoundCloud JavaScript is disabled You need to enable JavaScript to use SoundCloud Show me how to enable it Bharatt Chowrira, CEO & Eric Elenko, CoFounder & President of PureTech on Biotech Growth by Biotech2050 Podcast published on 2024-11-13T02:59:49Z Synopsis: In this insightful conversation on Biotech2050, host Rahul Chaturvedi sits down with Bharatt Chowrira, CEO, and Eric Elenko, Co-Founder and Preside
PureTech Announces Annual Results for Year Ended December 31, 2025 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Pres … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases PureTech Announces Annual Results for Year Ended December 31, 2025 April 29, 2026 | 19 min read Twitter LinkedIn Facebook Email Print Refined strategy and disciplined execution position Company to unlock value from its portfolio, which includes Celea Therapeutics’ Phase 3-ready deupirfenidone for idiopath … n, Massachusetts, 02210, United States. Shareholders are strongly encouraged to submit a proxy vote in advance of the meeting and to appoint the Chair of the meeting to act as their proxy. If a shareholder wishes to attend the meeting in person, we ask that the shareholder notify the Company by email to [email protected] to assist us in planning and implementing arrangements for this year’s AGM. Any specific questions on the business of the AGM and resolutions can be subm … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Pr … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference January 6, 2026 | 2 min read Twitter LinkedIn Facebook Email Print BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Sea … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis February 19, 2026 | 9 min read Twitter LinkedIn Facebook Email Print Designations provide market exclusivity as well as other d … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
PureTech Health plc – Half-Year Report 2025 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News &am … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases PureTech Health plc – Half-Year Report 2025 August 28, 2025 | 19 min read Twitter LinkedIn Facebook Email Print Achieved meaningful progress toward key value inflection points across our diversified portfolio, with multiple programs advancing into or toward late-stage development Launch of Celea Therapeut … with respect to cash, cash equivalents and short-term investments available to fund the Wholly-Owned Programs and make certain investments in Founded Entities. Non-IFRS Measures Reconciliation The following is the reconciliation of the amounts appearing in our Condensed Consolidated Statement of Financial Position to the alternative performance measure described above: (in thousands) June 30, 2025 December 31, 2024 Cash and cash equivalents $260,604 $280,641 Sh … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
PureTech Announces the Appointment of Robert Lyne as Chief Portfolio Officer - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opi … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business PureTech Announces the Appointment of Robert Lyne as Chief Portfolio Officer September 27, 2023 | 5 min read Twitter LinkedIn Facebook Email Print PureTech Health plc, a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, announced the … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
PureTech Appoints Robert Lyne as Chief Executive Officer - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases PureTech Appoints Robert Lyne as Chief Executive Officer December 18, 2025 | 5 min read Twitter LinkedIn Facebook Email Print BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science a … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML) - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML) April 22, 2026 | 13 min read Twitter LinkedIn Facebook Email Print Phase 1b dataset with LYT-200 demonstrates complete respo … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
PureTech to Present at Two Upcoming Investor Conferences - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases PureTech to Present at Two Upcoming Investor Conferences October 30, 2024 | 3 min read Twitter LinkedIn Facebook Email Print BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of pa … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults September 27, 2024 | 11 min read Twitter LinkedIn Facebook Email Print Milestone triggers payments to PureTech totaling $29 million under agreements with Royalty Pharma and PureTech’s F … outcome, and proceeds from the success of Cobenfy have enabled PureTech to self-fund the advancement of several programs – including LYT-100 (deupirfenidone), LYT-200 (anti-galectin-9 mAb), and the Glyph TM platform supporting the pipeline of Seaport Therapeutics. Bharatt Chowrira, PhD, JD, Chief Executive Officer of PureTech said: “Congratulations to the Karuna and BMS teams for delivering a groundbreaking treatment to people with schizophrenia. The FDA approval of Cobenfy i … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
PureTech Awarded up to $11.4 Million from U.S. Department of Defense to Advance LYT-300 (Oral Allopregnanolone) for Fragile X-associated Tremor/Ataxia Syndrome - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Devel … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Genetown PureTech Awarded up to $11.4 Million from U.S. Department of Defense to Advance LYT-300 (Oral Allopregnanolone) for Fragile X-associated Tremor/Ataxia Syndrome August 1, 2023 | 12 min read Twitter LinkedIn Facebook Email Print PureTech Health plc today announced that the company has been awarded up to $11.4 mil … their oral prodrug of allopregnanolone (LYT-300), and I am optimistic that this award will help accelerate the development of this potential first therapy for FXTAS.” An exploratory, open-label trial of six men with FXTAS, evaluated IV-administration of allopregnanolone across multiple neuropsychological and emotional tests. In addition to being well-tolerated, allopregnanolone showed signals of pharmacologic benefit across multiple neurological endpoints, including the Behav … e the safety, tolerability and efficacy of the drug in people with FXTAS. “This award from the DoD allows us to expand our evaluation of LYT-300, a candidate with a wide variety of potential indications, into FXTAS, an area of tremendous need where otherwise normally developed, aging individuals suffer from significant neurodegeneration,” said Eric Elenko, Ph.D., Chief Innovation Officer at PureTech Health. “We look forward to collaborating with Dr. Randi Hagerman and her tea … e pursuit of non-dilutive funding in the form of grants. This is the fourth DoD grant that PureTech has secured on behalf of its Wholly Owned Programs in addition to five grants secured on behalf of its Founded Entities. This work is supported by the Office of the Assistant Secretary of Defense for Health Affairs and the Defense Health Agency J9,
PureTech Health Affiliate Karuna Therapeutics Completes Extended $80 Million Series B Financing - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Deals PureTech Health Affiliate Karuna Therapeutics Completes Extended $80 Million Series B Financing April 1, 2019 | 8 min read Twitter LinkedIn Facebook Email Print Funding to drive investigation of further potential indications for lead product candidate, KarXT First U.S. Patent awarded for KarXT T … search Company, Eventide Asset Management, Pivotal bioVenture Partners, Partner Fund Management, Wellcome Trust, Sands Capital, Alexandria Venture Investments, and founder PureTech Health. Sofinnova Investments will hold an observer seat on Karuna’s board of directors. “We are grateful for the support of all our investors who share our commitment to developing and delivering novel therapies to patients with disabling neuropsychiatric disorders,” said Steve Paul, M.D., Karuna’ … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. Explore News Jobs Newslett … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
PureTech to Present at the Jefferies Global Healthcare Conference - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases PureTech to Present at the Jefferies Global Healthcare Conference May 22, 2025 | 2 min read Twitter LinkedIn Facebook Email Print BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
PureTech to Present at the SVB Securities Global Biopharma Conference - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions P … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Genetown PureTech to Present at the SVB Securities Global Biopharma Conference February 1, 2023 | 3 min read Twitter LinkedIn Facebook Email Print PureTech Health plc today announced that Daphne Zohar, Founder and Chief Executive Officer and Eric Elenko, Chief Innovation Officer, will participate in a fireside chat at t … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
Celea Therapeutics | PureTech Health - CHEST 2026 Skip to Main Content Celea Therapeutics | PureTech Health CHEST 2026 00 DAYS 00 HRS 00 MINS 00 SECS October 18 to October 21, 2026 Phoenix, Arizona Home Floor Plan Exhibitor List Login Create Account Celea Therapeutics | PureTech Health Booth #1259 About About Contact About Contact Name Celea Therapeutics | PureTech Health What We Do Celea Therapeutics (Celea) is dedicated to advancing transformative treatments for people with serious respiratory diseases. Drawn from the Latin word for “sky,” the name reflects the company’s mission to rise abov
--> December 2025 PureTech Health plc Results of Annual General Meeting on --> Login Start Free Trial Catalyst Calendar FDA Calendar Track key readouts and FDA decision dates in biotech and pharma. BPW Portfolio Bio Hedge Fund Shots and more... Historical FDA Calendar Review past FDA decisions and clinical readouts. Market Movers Track today's biotech market movers Biotech Earning Calendar Stay updated on biotech earnings. Historical PDUFA Dates Review past PDUFA dates and decisions. PDUFA Calendar Stay ahead of upcoming PDUFA dates Conference Calendar Keep up with biotech events. IPO Upcoming … p; past IPOs. Bio Pharma Screener Catalyst Sync™ Track biotech catalysts. Hedge Fund Screener Analyze hedge fund holdings. Company Screener Holistic company & pipeline analysis. All Stocks Holdings Explore hedge fund stock data. Heat-Map Market size & sector heat map. Inside Trades Monitor insider trading. Biotech Analyst Ratings Biotech analyst ratings & price targets M&A Tracker Track M&A deals and acquisition targets Resources News Latest biotech news.
Puretech Systems – World Border Security Congress Skip to content 13th-15th APRIL 2027 LISBON, PORTUGAL Home Who Should Attend Why Attend Conference Call for Papers Abstract Submittal Form Photo Gallery Outline Programme 2026 Speakers Conference Exhibition Exhibitor List Floorplan Exhibition Exhibiting Market Information Visitor Profile Why Participate Sponsors Sponsors Sponsorship Opportunities Become A Sponsor Contacts News Border Security Report Venue Venue REGISTRATION Terms & Conditions Privacy Policy Tag: Puretech Systems Industry News News Technology Watch our latest webinar … Attend The Organisers of the 2027 World Border Security Congress invite you to apply for your pass to attend the event in Lisbon, Portugal. Further details and to apply please click here >> Call for Papers Are you interested at speaking at the World Border Security Congress? Further details and to apply please click here >> Border Security Report Download the latest issue: May/June 2026 Issue: Vienna 2026 Madrid 2025 © Event copyright by Torch Marketing Co Ltd and KNM
Puretech,... - The United Kingdom Crowd Management Association Facebook Log In The United Kingdom Crowd Management Association's Post The United Kingdom Crowd Management Association February 12 · Shared with Public Puretech, CONNECTED TECHNOLOGY. PRACTICAL SOLUTIONS. SAFER OUTCOMES. Thank you to new member, Puretech for supporting Safer Crowds, Safer Venues 2026. Technology continues to play a vital role in how events are delivered and experienced, and organisations working across communications and infrastructure help keep teams connected when it matters most. Puretech has kindly support
PureTech Scientific LLC ISSA Show North America 2025 Log in Language Resource center Contact app support Legal Home Agenda Speakers PureTech Scientific LLC Featured Exhibitor 2822 Bookmark Team Information We are the Global Leader in High-Purity Glycolic Acid Innovation Headquartered in Belle, West Virginia, on the historic DuPont site, PureTech Scientific is the world’s leading manufacturer of ultra-high-purity glycolic acid (hydroxyacetic acid), supporting critical applications across the Life Sciences and Specialty Chemicals sectors. PureTech Scientific was established in August 2023 follow
Exhibitor Details Skip to content Press Escape to close the menu. Expand in-cosmetics Group Global 14/Apr/2026 Asia 03/Nov/2026 Bangkok International Trade & Exhibition Centre (BITEC) Korea 01/Jul/2026 COEX Convention & Exhibition Centre Latin America 23/Sept/2026 Connect Blog Covalo x in-cosmetics Collapse Global Navigation 6 - 8 April 2027 Barcelona, Spain Register interest Exhibitor enquiry About Reports & Insights Event History Past show review Steering Committee Partners Visit Prepare to visit Venue and travel Media and press Using your Smart Badge Covalo x in-cosmetics Awards
Puretech - The Security Event Europe 2027 Cookie Settings Skip To Main Content 27-29 April 2027 NEC Birmingham REGISTER YOUR INTEREST (opens in a new tab) BOOK A STAND (opens in a new tab) Home Visit Show submenu for: Visit Why Visit Platinum Club Exhibitor List Latest News Plan Your Visit Show submenu for: Plan Your Visit Lufthansa Airline Electronic Travel Authorisation (ETA) Show App Supporters Show submenu for: Supporters Founding Partners Premier Partners Event Partners 2026 Highlights FAQs Contact us Exhibit Show submenu for: Exhibit Why Exhibit Who Attends Book a Stand Download Sales Br … ll Name * Email Address * Contact Message * Please enter the code shown above * Submit Contact Request The Safety & Security Event Series QUICK LINKS Home Visit Exhibit Exhibitor List FAQs Contact Us Exhibitor Zone WHEN Tuesday 27th April 2027 10:00 - 16:30 Wednesday 28th April 2027 10:00 - 16:30 Thursday 29th April 2027 10:00 - 15:30 WHERE Hall 5 National Exhibition Centre (NEC) Birmingham B40 1NT UK ORGANISED BY © Copyright 2026 Privacy Policy Terms of U
Our Chief Executive Officer, Robert Lyne, and Co-founder & President, Eric Elenko, PhD, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Wednesday, March… | PureTech Health LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choice
Karuna Home Focus Scientific Focus Case Studies Team Team Board Collaborators Portfolio News Press Releases Publications Investors Share Information Sustainability Analyst Coverage Events & Presentations Corporate Governance Financials & Filings IR Resources Careers Contact Home Focus Scientific Focus Case Studies Team Team Board Collaborators Portfolio News Press Releases Publications Investors Share Information Sustainability Analyst Coverage Events & Presentations Corporate Governance Financials & Filings IR Resources Careers Contact Cobenfy™ (formerly known as KarXT) no … aruna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia November 17, 2023 PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia September 28, 2023 KarXT, invented at PureTech, submitted for FDA Approval in Schizophrenia March 23, 2023 PureTech Health and Royalty Pharma Enter into KarXT Royalty Agre
Bharatt Chowrira, CEO & Eric E… - Biotech 2050 Podcast - Apple Podcasts Search Home New Top Charts Search November 13, 2024 45 min Bharatt Chowrira, CEO & Eric Elenko, CoFounder & President of PureTech on Biotech Growth Biotech 2050 Podcast Play Synopsis: In this insightful conversation on Biotech2050, host Rahul Chaturvedi sits down with Bharatt Chowrira, CEO, and Eric Elenko, Co-Founder and President of PureTech Health. They explore the company’s pioneering R&D model and how it reshapes drug development by focusing on solving specific problems rather than pushing predefined s
Our CEO, Bharatt Chowrira, PhD, JD, and President and Founder, Eric Elenko, PhD, were recently featured on an episode of the Biotech2050 podcast. In this comprehensive conversation, they discussed… | PureTech Health LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Focus Home Focus Scientific Focus Case Studies Team Team Board Collaborators Portfolio News Press Releases Publications Investors Share Information Sustainability Analyst Coverage Events & Presentations Corporate Governance Financials & Filings IR Resources Careers Contact Scientific Focus Case Studies Home Focus Scientific Focus Case Studies Team Team Board Collaborators Portfolio News Press Releases Publications Investors Share Information Sustainability Analyst Coverage Events & Presentations Corporate Governance Financials & Filings IR Resources Careers Contact Across o … erapeutics, which conducted late-stage development before submitting a New Drug Application to the FDA and ultimately being acquired by Bristol Myers Squibb for $14 billion. SEE OUR PROGRAM Celea's Deupirfenidone Deupirfenidone is currently in development for the treatment of idiopathic pulmonary fibrosis (IPF) and is a deuterated form of pirfenidone, which is one of the two standard-of-care treatments approved to treat IPF, in addition to nintedanib. Deuteration is intended
ISC West - Exhibitor Details Skip to content Press Escape to close the menu. Open Menu ISC News ISC West Mar-82-2026 ISC East Javits Center, NYC Collapse Global Navigation April 5-9, 2027 The Venetian Expo, Las Vegas REGISTRATION INQUIRY ATTEND Why Attend? Convince Your Boss Attendee Resources EXPLORE Hours & Location Exhibitor Directory Product Directory Show Events Show Map DISCOVER What's Happening Digital Trust & Identity Cybersecurity & Convergence ISC® StartUps Security Experience Center SIA New Products + Solutions (NPS) Awards ISC Pro EXHIBIT Why Exhibit? Interested in
PureTech to Present at The SVB Leerink 10th Annual Global Healthcare Conference - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Genetown PureTech to Present at The SVB Leerink 10th Annual Global Healthcare Conference February 18, 2021 | 4 min read Twitter LinkedIn Facebook Email Print PureTech Health plc announced that Bharatt Chowrira, Ph.D., J.D., President and Chief of Business and Strategy, George Farmer, Ph.D., Chief Financial Officer, and … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Akcie PureTech Health plc (PRTC): dokumenty, prezentace a earnings calls AI Nástroje Kaledář zisků Super investoři Connector Ceník Registrace Přihlášení Zkusit zdarma PureTech Health plc PRTC Cena: Valuace 100 Růst 30 Zdraví 75 Souhrn Finanční data Pro investory Dokumenty Předpovědi Dividendy Zisky Návštěvnost webu Souhrn Finanční data Pro investory Dokumenty Předpovědi Dividendy Zisky Návštěvnost webu Shrnutí Výsledky Q4 2025 Apr 2026 Výsledky Q2 2025 Aug 2025 Výsledky Q4 2024 Apr 2025 Transcript Slides Výsledky Q4 2025 Načítám obsah… AI Shrnutí Výsledky Q4 2025 Funkce shrnutí j
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Puretech to Sponsor ISPE UK Annual Conference & Awards Dinner 2025 - Puretech Systems Limited Skip to content MENU MENU About Sectors Pharmaceutical & BioTech System Design Pipework Installation System Skids Pre-Treatment WFI Generation Purified Water (PW) Pure Steam Generation CIP / SIP Storage & Distribution Mixing Vessels Turnkey Projects Manufacturing Capabilities Medical Gases System Design Pipework Installation Turnkey Projects Manufacturing Capabilities Data Centres System Design Pipework Installation Water Systems Turnkey Projects Manufacturing Capabilities Semiconductor System Des
#biofuture2023 | PureTech Health LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Cookie Policy .
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
#jpm26 | PureTech Health LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Cookie Policy . Skip to
OTC Markets | Official site of OTCQX, OTCQB, OTCID and Pink Limited Markets You need to enable JavaScript to run this app.
PureTech licenses ‘bacterial cocktail’ to boost cancer immunotherapy Skip to main content Saturday 27 June 2026 BlueSky linkedin youtube header links Get Newsletters Media Kit Pharmaphorum menu first category News Views & Analysis Deep Dive Equity and Sustainability Research & Development Market Access Oncology Artificial Intelligence Patients & Partnerships GLP-1 Previous Editions Webinars Podcasts Videos Spotlight on ASCO BIO-Europe C-Suite Innovators ESMO Frontiers Health JP Morgan Global Policy Insights Events close SECTION News Views & Analysis Deep Dive Research & Dev … ining defined bacterial ingredients, into the clinic. It plans to file an application to begin clinical trials with the FDA next year. [caption id="attachment_33402" align="alignnone" width="181"] Bernat Olle[/caption] Bernat Olle, CEO of Vedanta Biosciences, said: “Dr Honda’s research suggests an entirely new approach to cancer immunotherapy harnessing the human microbiome, which has the potential to significantly enhance the effectiveness of cancer therapies.” Vedanta
PureTech Health | ApexOnco - Clinical Trials news and analysis Skip to main content x Main navigation HOME Content Conferences Data insights Deals Interviews Regulatory Trial results “The team is super responsive to my inquiries and suggestions” --> Chief Business Officer US public biotech company Click here for more information Search Sign in Breadcrumb Home / PureTech Health “The insights provided by the analysts are great” Andrea Gnirke-Maier --> Director New Product Planning Morphosys Click here for more information Pagination Previous page ‹‹ Page 61 Subscribe to PureTech Heal
0VQ : PURETECH HEALTH PLC - MSN Money Popolare USDEUR ▼ -0,14% BTC ▲ +1,39% EURGBP ▲ +0,05% ETH ▲ +2,17% BNB ▼ -0,28% ENEL ▲ +0,34% TSLA ▲ +1,22% ADA ▲ +2,14% FTSEMIB ▼ -1,00% XRP ▲ +3,09% Portafoglio personale INIZIA IL TUO PERCORSO DI INVESTIMENTO Tieni traccia e monitora i tuoi investimenti, tutto in un’unica posizione. Fai clic sull'icona per aggiungere un titolo alla tua watchlist. Suggerito per te USD/EUR Euro 0,88 -0,14% Bitcoin BTC 52.845,50 +1,39% EUR/GBP Sterlina inglese 0,86 +0,05% Ethereum ETH 1.386,69 +2,17% BNB BNB 49
February 14, 2025 - Volume 26, Number 22 | Harvard-MIT Health Sciences and Technology Skip to main content this WEEK in HST February 14, 2025 Volume 26, Number 22 ‹ Previous Issue Next Issue › HST Community Notices MEMP PhD Thesis Defense Announcements IMES Faculty Promotions An Invitation to the HST/IMES Community: WOZA African Cultural Night MIT Global Support Resources: Registering your Travel Help Spread the Word - HST! Course & Academic Resources HST.590 Biomedical Engineering Seminar Series - Spring 2025 Schedule Spring 2025 Course Opportunity: 16.459 - Bioastronautics Journal Semina … Community Fellows Positions MITAC Opportunities Office of Graduate Education - Fellowship Workshops & Financial Literacy Resources International Students Office Newsletter MIT GradDiversity & ICEO Newsletters MIT Spouses & Partners Connect and MIT Language Conversation Exchange Professional Opportunities MPM BioImpact Summer Fellowship Info Session PureTech Health Job Opportunity MIT J-WAFS Fellowship for Water Solutions ADI Bioelectronic Platforms Research Inter … Ramanan , PhD; Third Rock Ventures Partner Aleks Radovic-Moreno, PhD; Longwood Fund Partner April 3 Negotiations Samuel (Mooly) Dinnar , PMD, Instructor at MIT; lecturer at Harvard Negotiation Institute April 10 Drugs/Devices/Data Panel Speaker TBD April 17 Catalyst Connect Student presentations from HST.207 April 24 FDA Regulation Peter Marks , MD PhD; Director, FDA Center for Biologics Evaluation and Research SPRING 2025 COURSE OPPORTUNITY: 16.459 - BIOASTRONAUTICS JOURNAL … ns team. Friday, March 14 from 3-6pm at 20 Overland Street, Boston MA RSVP HERE Deadline to RSVP is Thursday, February 27 Whether you're interested in scientific innovation, entrepreneurship, or career opportunities, this is a great chance to connect and learn. HBC INTERNATIONAL INITIATIVE SPEAKER SERIES The International Initiative of GSAS Harvard Biotech Club invites you to the next installment of this speaker series. Shaping an International Career in Biotech - My Journey … ke University in a variety of faculty roles, including the Director of the Slay Fund for Social Justice (since 2023) and Associate Dean of Strategic Initiatives in the College of Arts and Sciences (since 2024). Her primary field of study is social psychology. Dr. Allen teaches courses in experimental social psychology, psychology of prejudice and
PureTech to research Alzheimer's drugs based on 'brain drain' theory | pharmaphorum Skip to main content Saturday 27 June 2026 BlueSky linkedin youtube header links Get Newsletters Media Kit Pharmaphorum menu first category News Views & Analysis Deep Dive Equity and Sustainability Research & Development Market Access Oncology Artificial Intelligence Patients & Partnerships GLP-1 Previous Editions Webinars Podcasts Videos Spotlight on ASCO BIO-Europe C-Suite Innovators ESMO Frontiers Health JP Morgan Global Policy Insights Events close SECTION News Views & Analysi
--> PureTech Health plc 6 Tide Street, Suite 400, Boston, MA 02210 Tel 617.482.2333 Fax 617.482.3337 puretechhealth.com This letter is being sent to the shareholders of PureTech Health plc (the Company ) for information only --> Login Start Free Trial Catalyst Calendar FDA Calendar Track key readouts and FDA decision dates in biotech and pharma. BPW Portfolio Bio Hedge Fund Shots and more... Historical FDA Calendar Review past FDA decisions and clinical readouts. Market Movers Track today's biotech market movers Biotech Earning Calendar Stay updated on biotech earnings. Historical PDUFA Dates … p; past IPOs. Bio Pharma Screener Catalyst Sync™ Track biotech catalysts. Hedge Fund Screener Analyze hedge fund holdings. Company Screener Holistic company & pipeline analysis. All Stocks Holdings Explore hedge fund stock data. Heat-Map Market size & sector heat map. Inside Trades Monitor insider trading. Biotech Analyst Ratings Biotech analyst ratings & price targets M&A Tracker Track M&A deals and acquisition targets Resources News Latest biotech news.
SC 13D/A 1 d829078dsc13da.htm SC 13D/A SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Karuna Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 48576A100 (CUSIP Number) PureTech Health LLC 6 Tide Street, Suite 400 Boston, MA 02210 (617) 482-2333 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) May 22, 2020 (Date of Event Which R … ept as described above, none of the Reporting Persons currently has any plan or proposal that relates to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D. Item 5. Interest in Securities of the Issuer a) As of the date hereof, the Reporting Persons may be deemed, for purposes of Rule 13d-3 of the Act, directly or indirectly, including by reason of their mutual affiliation, to be the beneficial owners
Iron Path-backed PureTech picks up Cymer Chemical's Dayton, Tennessee operation | PE Hub Sign in or Register Sign In / Register Database GP search Update your database profile Private equity dealmaking data Quick Search News Briefs Financial Services Healthcare Technology Energy & Power Business Services Consumer & Retail Industrial & Manufacturing Women in Private Equity Deals of the Year Sports/ Entertainment News & Analysis Deals People Opinion Deep Dives Podcasts Research Quarterly M&A Deals Bookstore Events Global events calendar Contact us Sign-in FAQ About
BioCentury - PureTech turns inward This Edition ARTICLE | Product R&D PureTech turns inward How PureTech is transitioning from the affiliate model to an internal pipeline Lauren Martz, Associate Editor January 11, 2019 3:38 AM UTC After a 15-year run of spinning out technologies into affiliate companies, PureTech Health plc is stepping away from that model in favor of an internal pipeline to advance its new platforms. Behind the structural shift is a convergence of new leadership, complementary technology platforms involving the brain-immune-gut axis and a strong financial position. ... BC
Border Security Insight: A Collaborative Event by SIA and PureTech Systems in Hosting CBP PMOD Deputy Directorate Chief Henry Laxdal Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Mult … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
🥊 Proud Sponsor Alert! 🥊 PureTech is... - PureTech Security Facebook Log In PureTech Security's Post PureTech Security October 25, 2024 · Shared with Public Proud Sponsor Alert! PureTech is thrilled to support Spring Hill Boxing Club through one of our valued partners, David Mullen from DSM Security! We’re honoured to back these talented athletes as they gear up for their upcoming trip to Sweden. Wishing the team all the luck and success in the ring – bring home the victory! #PureTech #SpringHillBoxing #Sponsorship #TeamSupport #BoxingClub #GoodLuck All reactions: 8 4 comments 2 shares
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
🎉 New year, new sponsor! We are thrilled to announce the latest company to join our sponsorship programme is PureTech Security.🤝 In this exciting partnership, Skills for Security and PureTech… | Skills for Security LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices a
PureTech Scientific Acquires Cymer Chemical's Facility | PureTech Scientific posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in … ch teams in achieving superior product outcomes through precision chemistry and application-specific development. Website: https://newos-gmbh.de/en/ Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in 1,212 followers View Profile Follow Explore content categories Career Productivity Finance Soft Skills & Emotional Intelligence Project Management Education Technology Leadership Ecommerce User Experience Recruitment & HR Customer Experience Rea
EX-99.1 2 a991pressrelease.htm EX-99.1 Document Exhibit 99.1 28 August 2024  PureTech Health plc – Half-Year Report Strong progress across PureTech’s portfolio, with significant near-term catalysts Robust shareholder returns enabled by Founded Entity 1 monetization; $100 million Tender Offer and $50 million buyback completed Strong balance sheet with expected operational runway for at least three years Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or … uba Greenwood, JD, Managing Partner of the Dana-Farber Cancer Institute Venture Fund, Binney Street Capital, and former Chief Executive Officer and Board Chair of Kojin Therapeutics. • Announced in the August 2024 post-period that Michele Holcomb, PhD, will join PureTech’s Board of Directors as an independent non-executive director on September 23, 2024. Founded Entities • Karuna Therapeuti cs (“Karuna”) was acquired by BMS in March 2024 for a to … in patients with rCDI and is intended to form the basis for a Biologics License Application (“BLA”) to be filed with the FDA. It also expects topline data from its Phase 2 COLLECTiVE202 clinical trial of VE202 for the treatment of ulcerative colitis (“UC”) in 2025. Vedanta also expects to initiate a Phase 1 trial of VE707 for the prevention of multidrug-resistant infections in 2025. About PureTech Health  PureTech is a clinical-stage b … with respect to cash, cash equivalents and short-term investments available to fund the Wholly-Owned Programs and make certain investments in Founded Entities. Non-IFRS Measures Reconciliation The following is the reconciliation of the amounts appearing in our Condensed Consolidated Statement of Financial Position to the alternative performance measure described above: (in thousands) June 30, 2024 December 31, 2023 Cash and cash equivalents 308,478 191,081 Short-term inv
PureTech Health plc (Form: 6-K, Received: 12/18/2025 07:00:41) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December, 2025 Commission File Number 001-39670 PURETECH HEALTH PLC (Translation of registrant’s name into English) 6 Tide Street, Suite 400 Boston, Massachusetts 02210 (Address of principal executive offices) Indicate by check mark whether
PureTech Health posts 2025 loss, details cash runway | PRTC SEC Filing - Form 6-K --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto … d cash equivalents as of March 31, 2026 Total revenue $4.7 million Contract and grant revenue for year ended December 31, 2025 General and administrative expenses $46.6 million Year ended December 31, 2025; down 35% from 2024 Research and development expenses $56.6 million Year ended December 31, 2025; down 19% from 2024 Net income (loss) attributable to owners ($109.7 million) Net loss for year ended December 31, 2025 Prior-year net income $53.5 million Net income attributab … n, Massachusetts, 02210, United States. Shareholders are strongly encouraged to submit a proxy vote in advance of the meeting and to appoint the Chair of the meeting to act as their proxy. If a shareholder wishes to attend the meeting in person, we ask that the shareholder notify the Company by email to [email protected] to assist us in planning and implementing arrangements for this year’s AGM. Any specific questions on the business of the AGM and resolutions can b … ne and royalty rights. This structure has historically enabled PureTech to self-fund the advancement of our portfolio through key catalysts without relying on traditional dilutive capital raises at the parent company level. Following the completion of Celea’s financing, we expect to reduce our operational burn significantly compared to our historical run rate, with a lower and more predictable cost base going forward. This will be driven in part by the transition of the … ue-driving milestones with modest spend before leveraging external investors to fund later development. It also provides multiple “shots on goal,” diversifies risk across our Portfolio, and enables us to progress more potential therapies toward patients. Crucially, this model allows us to generate reproducible value creation without i
Puretech Health Plc Regulatory Milestones - GlobalData Visit Corporate Site Sign in Search Menu Sign In Who We Are Who We Are Your powerful market insights platform. Book a demo Mission & Values Clients Media People Why GlobalData Resource Center CSR Partners Careers History Investors Industries We Cover Industries We Cover Your curated industry news round-up. Subscribe now Aerospace, Defense & Security Agribusiness Apparel Automotive Banking & Payments Construction Consumer Foodservice Healthcare Insurance Medical Devices Mining Oil & Gas Packaging Pharmaceutical Power Public
Home - PureTech Health Home Focus Scientific Focus Case Studies Team Team Board Collaborators Portfolio News Press Releases Publications Investors Share Information Sustainability Analyst Coverage Events & Presentations Corporate Governance Financials & Filings IR Resources Careers Contact Home Focus Scientific Focus Case Studies Team Team Board Collaborators Portfolio News Press Releases Publications Investors Share Information Sustainability Analyst Coverage Events & Presentations Corporate Governance Financials & Filings IR Resources Careers Contact We are dedicated to g
PureTech Health | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas PureTech Health Website: PureTech Health Business Area(s) Biologics Digital Medicines Small Molecules COVID-19 Description PureTech Health is harnessing the latest insights from human biology to develop new categories of medicine that combines chemical treatments with digita
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Puretech's CEO Bharatt Chowrira Steps Down — TradingView News Search Products Community Markets Brokers More EN Get started News / Reuters / Puretech's CEO Bharatt Chowrira Steps Down Puretech's CEO Bharatt Chowrira Steps Down Refinitiv Less than 1 min read PRTC PureTech Health PLC PRTC : PURETECH ANNOUNCES LEADERSHIP TRANSITION PURETECH HEALTH PLC - BHARATT CHOWRIRA STEPS DOWN AS PURETECH CEO AND BOARD MEMBER PURETECH HEALTH PLC - ROBERT LYNE APPOINTED AS INTERIM CEO OF PURETECH Reuters US stocks © Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.c
PureTech Announces Annual Results for Year Ended December 31, 2025 – Company Announcement - FT.com Subscribe Sign In Menu Search Financial Times myFT if you don't need to support both core and enhanced --> Search the FT Search Search the FT Search Close Home World US Companies Tech Markets Climate Opinion Lex Stock Picking Game Life & Arts How To Spend It Sign In Subscribe Markets Markets Data Equities Equities Screener Sectors & Industries Company Announcements Director Dealings World Markets Financial Times Close International Edition UK Edition Search the FT Search Top sections Home … Massachusetts , 02210, United States . Shareholders are strongly encouraged to submit a proxy vote in advance of the meeting and to appoint the Chair of the meeting to act as their proxy. If a shareholder wishes to attend the meeting in person, we ask that the shareholder notify the Company by email to [email protected] to assist us in planning and implementing arrangements for this year’s AGM. Any specific questions on the business of the AGM and resolutions can be subm … ne and royalty rights. This structure has historically enabled PureTech to self-fund the advancement of our portfolio through key catalysts without relying on traditional dilutive capital raises at the parent company level. Following the completion of Celea's financing, we expect to reduce our operational burn significantly compared to our historical run rate, with a lower and more predictable cost base going forward. This will be driven in part by the transition of the Celea … ue-driving milestones with modest spend before leveraging external investors to fund later development. It also provides multiple “shots on goal,” diversifies risk across our Portfolio, and enables us to progress more potential therapies toward patients. Crucially, this model allows us to generate reproducible value creation without incurring the costs and overhead necessary to scale into a fully integrated commercial organization. We believe our greatest strength within the … ulting amount of any gain or loss is recognized. Whilst we do not plan to fully fund our deupirfenidone (LYT-100) or LYT-200 programs, we anticipate that we will invest in the respective Founded Entities that house those programs, Celea Therapeutics and Gallop Oncology, in conjunction with external investors. We also anticipate we will be providi
PureTech Ponders Way Forward As CEO Exits Pink Sheet Scrip Medtech Insight HBW Insight Generics Bulletin In Vivo Spotlight China Obesity AI Drug Pricing Cell & Gene Therapies Business Deals Financing Earnings Commercial Strategy Approvals & Launches Trial Results Market Access Disease Cancer Immune Disorders Cardiovascular Neurological Rare Diseases Deep Dives Interviews Data Insights Scrip Asks Disease Landscapes Focus On Asia Japan South Korea India Scrip Asia 100 Tools & Trackers Pipeline Watch Finance Watch Deal Watch Stock Watch Top Selling Drugs Company Rankings Executive Mov … st Spotify About About Us Opens in new window Meet the Team Editorial Standards Award-Winning Journalism Help Advertise Opens in new window Contact Us Evaluate Home Account My Account My View Email Preferences Start Free Trial Opens in new window More Scrip Perspectives Scrip 100 Ranking Scrip Asia 100 Conferences Executives On The Move Pipeline Watch Terms and Conditions Opens in new window Privacy Policy Opens in new window
PureTech Appoints Robert Lyne as CEO | Company Announcement | Investegate Fundraise Welcome About Contact Us Help Home Companies Advanced search Archive UK Short Positions Meetings UK Newswire New Login Register PureTech Appoints Robert Lyne as CEO Summary by AI BETA Close X PureTech Health plc has appointed Robert Lyne as Chief Executive Officer, effective immediately, following his tenure as Interim CEO since July 2025. The company's immediate focus is on securing funding for its new entity, Celea Therapeutics, with an expected close in the first half of 2026, after which PureTech's operatio … rms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com . RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock
%PDF-1.6 %���� 4691 0 obj > endobj 4703 0 obj >/Filter/FlateDecode/ID[ ]/Index[4691 21]/Info 4690 0 R/Length 80/Prev 2489669/Root 4692 0 R/Size 4712/Type/XRef/W[1 3 1]>>stream h�bbd```b``= "_�Ik��D� �� `��@��9��~H2��Մ���m3�� �D�f �3��� �x� endstream endobj startxref 0 %%EOF 4711 0 obj >stream h�b```�� � ,;�@(������7CAE�Pa+��b � ��=!�@E�/2ʔ Ɠ�BD|>�,� �O' N�pS�ؖb����� �1�8��U�_z�x����ܖҥSzu�m`A cV���'��#�� >/Metadata 347 0 R/OCProperties >/OCGs[4704 0 R]>>/Outlines 844 0 R/PageLayout/SinglePage/Pages 4681 0 R/StructTreeRoot 933 0 R/Type/Catalog>> endobj 4693 0 … :19d17d8e-cdf1-44c0-815e-c067bbc70fe9 uuid:d3698296-1bc8-4ba5-87cd-89f5f6cac26d application/pdf Kana DeLuca Adobe PDF Library 26.1.59 0x010100A0C61C07D73F364A828025BA51642606 endstream endobj 348 0 obj >stream hޜ��N1De��{��Y��P�DQ:D��DB��#{�)A��fl��ά�E%���D�53�.ݸX�&dvo&�[m�Hh�Y$j��� �v�����UܧǷ��S'9L���0y�2�2Lm�y:�|�����^��۔C*�ڿ��������r���O^ E��AFԹ��V�Z�59uCBUTUEK�DŶ�uԹE*rk0ilI�������ܧ� PK�X���x��h%��-�C3�66���KP��C��� endstream endobj 349 0 obj >stream
[20-F] PureTech Health plc Files Annual Report (Foreign Issuer) | PRTC SEC Filing - Form 20-F --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI S … eding 12 months (or for such shorter period that the registrant was required to submit such files):    Yes   ☒    No  ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” and “emerging growth company” in Rule 12b-2 of the Exchan … re costly to conduct than we anticipate, any of which can affect our ability to fund our company and would have a material adverse impact on our platform or our business. — If we encounter difficulties enrolling patients in clinical trials, our clinical development activities could be delayed or otherwise adversely affected. — Use of the therapeutic candidates within our Wholly-Owned Programs or the therapeutic candidates being developed by our Founded Entities co … a material adverse impact on our business, results of operations and ability to fund our business. — Our business is highly dependent on the clinical advancement of our programs and our success in identifying potential therapeutic candidates. Delay or failure to advance our programs could adversely impact our business. — Our future success depends on our ability to retain key employees, directors, consultants and advisors and to attract, retain and motivate qualif … , FibroGen’s FG-3165. The FDA cleared FibroGen's Investigational New Drug Application, or IND,  for FG-3165 in June2024 for the treatment of solid tumors. There may be other academic groups and/or companies that are involved in pre-clinical research centered around galectin-9 as a therapeutic target. In the field of acute myeloid leuke
I’m honoured to be appointed Chief Executive Officer of PureTech. PureTech has a strong foundation: exceptional people, differentiated science, and a model designed to translate innovation into real… | Robert Lyne | 50 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update you
EX-99.1 2 d778852dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 25 April 2024 PureTech Health plc PureTech Announces Annual Results for Year Ended December 31, 2023 Significant operational and clinical progress in 2023 and early 2024 with maturation of Internal Programs, 1 launch of two new Founded Entities, 2 including a $100 million Series A financing for Seaport, and the $14 billion acquisition of Karuna by Bristol Myers Squibb Robust balance sheet with PureTech level cash, cash equivalents and short-term investments of $326.0 million 3 and consolidated cash, cash equivalents a … nbsp; • The U.S. Food and Drug Administration accepted its New Drug Application for KarXT and a decision is expected by September 26, 2024. If approved, KarXT will be the first new mechanism in over 50 years for patients with schizophrenia. • Bristol Myers Squibb (NYSE: BMY) acquired Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion in the 2024 post-period. PureTech received approximately $293 … activities. The syndicate was co-led by new investors AXA IM and The AMR Action Fund along with existing investors including The Bill & Melinda Gates Foundation and PureTech. • Vedanta announced the publication of Phase 2 study results from its lead program, VE303, in the Journal of the American Medical Association (JAMA). • Akili (Nasdaq: AKLI): • Akili announced positive data from a pivot … • Akili released EndeavorOTC ® 10 and submitted a 510(k) application to the FDA for EndeavorOTC as an over-the-counter treatment for adults with ADHD. • Akili announced plans to pursue regulatory approval for over-the-counter labeling of its treatment products and expects that both EndeavorOTC and EndeavorRx will remain on the market as the company pursues these plans. • Vor (Nasdaq: VOR) … treet, London EC1A 4HD, United Kingdom. Shareholders are strongly encouraged to submit a proxy vote in advance of the meeting and to appoint the Chair of the meeting to act as their proxy. If a shareholder wishes to attend the meeting in person, we ask that the shareholder notify the Company by email to [email protected] to assist us in plann
LYT-200 Home Focus Scientific Focus Case Studies Team Team Board Collaborators Portfolio News Press Releases Publications Investors Share Information Sustainability Analyst Coverage Events & Presentations Corporate Governance Financials & Filings IR Resources Careers Contact Home Focus Scientific Focus Case Studies Team Team Board Collaborators Portfolio News Press Releases Publications Investors Share Information Sustainability Analyst Coverage Events & Presentations Corporate Governance Financials & Filings IR Resources Careers Contact Targeting galectin-9 to unlock new p
Careers Home Focus Scientific Focus Case Studies Team Team Board Collaborators Portfolio News Press Releases Publications Investors Share Information Sustainability Analyst Coverage Events & Presentations Corporate Governance Financials & Filings IR Resources Careers Contact Home Focus Scientific Focus Case Studies Team Team Board Collaborators Portfolio News Press Releases Publications Investors Share Information Sustainability Analyst Coverage Events & Presentations Corporate Governance Financials & Filings IR Resources Careers Contact Make a Difference PureTech Health 6
PureTech Health plc (PRTC.Y) Leadership & Management Team Analysis - Simply Wall St Dashboard Portfolios Watchlist Community Discover Screener NOT FOR DISTRIBUTION PureTech Health plc OTCPK:PRTC.Y Stock Report Market Cap: US$421.5m Portfolio Add to Portfolio Holding More actions … Portfolio Add to Portfolio Holding … Company Overview 1 Valuation 2 Future Growth 3 Past Performance 4 Financial Health 5 Dividend 6 Management 7 Ownership Other Information Stock Community View Dividend PureTech Health Management Management criteria checks 3/4 PureTech Health's CEO is Rob Lyne, appointed in … ment will be treated as a statement to which Rule 2.8 of the Code applies. This deadline can be extended with the consent of the Takeover Panel in accordance with Rule 2.6(c) of the Code. Announcement • Feb 12 Puretech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with Up to 55% Drug Absorption Via Lymphatics with Glyph Platform PureTech Health plc noted that its Founded Entity, Seaport Therapeutics, … rvard College and an M.D. from Johns Hopkins University School of Medicine. His residency was in psychiatry at the Tufts-New England Medical Center. He is a member of the American Academy of Pharmaceutical Physicians and the American Psychiatric Association. Announcement • Jun 20 PureTech Health plc Appoints Raju Kucherlapati as Chair of Board of Directors PureTech Health plc announced that Raju Kucherlapati, PhD, has been appointed Chair of the Board of Directors, effective … other of the Year, and the Johnson & Johnson Special Recognition Leadership Award for her work in diversity and inclusion. Mr. Green steps into the role of Chief Operating Officer bringing nearly 25 years of biopharmaceutical development, commercialization and operational experience. Most recently, Mr. Green was Senior Vice President, Head of Development Programs at Alnylam Pharmaceuticals where he led a team responsible for global development and pre-commercialization ac
Careers Home Focus Scientific Focus Case Studies Team Team Board Collaborators Portfolio News Press Releases Publications Investors Share Information Sustainability Analyst Coverage Events & Presentations Corporate Governance Financials & Filings IR Resources Careers Contact Home Focus Scientific Focus Case Studies Team Team Board Collaborators Portfolio News Press Releases Publications Investors Share Information Sustainability Analyst Coverage Events & Presentations Corporate Governance Financials & Filings IR Resources Careers Contact Make a Difference PureTech Health 6
Brenntag Specialties signs strategic distribution agreement with PureTech Scientific for glycolic acid solutions in North America | Brenntag Brenntag Germany Contact us Career Corporate Germany (English) Open menu Log in Products Industries Services Sustainability About Sitemap Media News Mar 4, 2025 Brenntag Specialties signs strategic distribution agreement with PureTech Scientific for glycolic acid solutions in North America C ustomers in the U.S., Canada and Mexico will benefit from access to the Glypure® product line in the Beauty and Care markets Brenntag, the global market leader in che
PureTech Health CEO Bharatt Chowrira Steps Down; Names Robert Lyne Interim CEO Business Business Latest Headlines Top Stories Breaking News Earnings Biotech Investors Stock Alerts IPOs M&A Canadian UK Wallstreet Events Industry News Industry News Technology Software Banking Automotive Energy More Corp. Calendars Dividends Stock Splits Buybacks Conference Calls Earnings Calendar Earnings Calendar Pos Pre-announcements Profit Warnings Positive Surprise Negative Surprise Latest Earnings FDA Calendars Drug Approvals Clinical Trial Calendar Ratings Changes Upgrades Downgrades Cov Initiations Co … Emailed Jamieson Wellness Conducts Strategic Review After Unsolicited Takeover Proposal June 25, 2026 02:24 ET Serco Group H1 Underlying Profit, Revenues Rise, Backs FY26 Outlook; North America CEO To Resign June 25, 2026 03:05 ET Alphabet Shares Fall As AI Talent Departures And Competitive Concerns Weigh On Investors June 22, 2026 17:53 ET SGH Approves Up To AUD 500 Mln On-Market Share Buyback June 22, 2026 01:18 ET Boundless Bio Merges Serapha Bio; Raise $230 Mln In Privat
Iron Path Capital-backed PureTech Scientific Completes Acquisition of Glycolic Acid Business from The Chemours Company | Iron Path Capital Skip to content Menu Strategy Operational Partnership Investment Approach Iron Path Values Portfolio Partnership Executive-in-Residence Program Team Media Center Contact Us Investor Login Iron Path Capital-backed PureTech Scientific Completes Acquisition of Glycolic Acid Business from The Chemours Company Posted on August 1, 2023 August 1, 2023 by hammersmith Deal Creates Standalone Operating Company Focused on Superior Customer Support, Sustainability, and … the Iron Path team. They are not provided to solicit investors in an Iron Path fund. The portfolio company executive featured in this endorsement is not an investor in an Iron Path fund and no compensation was provided for such testimonial. **The specific investment identified is not representative of all of the investments purchased, sold, or recommended and it should not be assumed that the investment identified was or will be profitable. No guarantee of investment perform … ormance is not indicative of future results. Actual holdings will vary for each fund. A list of all investments is available upon request. Contact: Rob Reistetter [email protected] GET IN TOUCH STRATEGY PORTFOLIO TEAM MEDIA CENTER Copyright 2026. Iron Path Capital. All rights reserved. Privacy Policy | Terms of Use Rob Reistetter Managing Partner Rob co-founded Iron Path Capital in 2021, co-leads the firm’s private equity execution and leads Iron Path’s internal operatio … ector at Sole Source Capital in Dallas, a $555m middle market industrial buyout fund. As Head of Origination, Ian managed a team of professionals responsible for building relationships with intermediaries and business owners to source proprietary investment opportunities for the firm. Earlier in his career, Ian was a director at Harris Williams, a middle market investment bank, where he executed sell-side and buy-side deals across numerous sub-sectors within specialty industr … neering from the U.S. Naval Academy and an M.B.A from Wharton. Pamela Moko Defo Fund Controller Pamela joined Iron Path Capital in May 2026 and has more than 15 years of experience in investment accounting. Most recently, she served as Investment Accounting Manager with Strategic Investment Group. At Iron Path Capital, Pamela is responsible for o
U.S. Glycolic Acid Manufacturer | Bulk Supply & Tolling | PureTech Scientific Skip to site content Industries & Products Personal Care All Products Glypure® 70 ULTRA Glypure® 70 Glypure® 99 Glypure® GL Clean & Disinfect All Products Glyclean® D Glyclean® D70 Glyclean® D70E Glyclean® 70 Specialties All Products Glypure® PGA Glyclean® Electronics Glyclean® AN Industrial All Products Glycolic Acid 70% Technical Solution Glycolic Acid 70E Oil & Gas All Products Glysolve™ O&G 70% About Us Contact Us Industries & Products Personal Care All Products Glypure® 70 ULTRA Glypure® 70 Glypure® 99 Glypu … l address, you agree to our Privacy Policy , Cookie Policy , and Terms of Use . Submit --> 901 W. Dupont Ave. Belle, West Virginia 25015 1-888-536-9836 ©2026 PureTech Scientific. All rights reserved. Privacy Policy Cookie Policy Terms of Use Find us on Personal Care Clean & Disinfect Specialties Industrial Oil & Gas About Us Contact Us Careers Review Safety Data Sheets